CNBX - Cannabics Pharmaceuticals posts final results from RCC-33 mice cancer study

Cannabics Pharmaceuticals ([[CNBX]]) announces the final results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice.The final study results showed a significant and robust inhibitory effect on tumor growth, as evidenced by a 33% reduction in tumor volume in mice exposed to RCC-33 in comparison with sham control mice (p £ 0.016), Cannabics said.Both the experimental and the control groups were inoculated with human colorectal cancer cells, with daily doses of intraperitoneal ((IP)) delivery of RCC-33 or sham control initiated at day 5.The study was concluded after 16 days of treatment (day 21) when a member of the control group reached a predetermined tumor size.

For further details see:

Cannabics Pharmaceuticals posts final results from RCC-33 mice cancer study